Comparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients

Author(s):
Sakineh BaghbeheshtiSakineh Baghbeheshti1, Shadi BaniasadiShadi BaniasadiShadi Baniasadi ORCID2,*
1Dept. of Toxicology & Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2-Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Koomesh:Vol. 21, issue 3; e153948
Published online:Aug 21, 2019
Article type:Research Article
How to Cite:Baghbeheshti S, Baniasadi S. Comparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients. koomesh. 2019;21(3):e153948. doi:

Abstract

Similar Articles

31
May
2021

Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital

Jeeshma Varghese,
Uday Mateti,
Jayarama Shetty,
Malona Lilly Philip,
Barma Naga Raju

Varghese J, Mateti U, Shetty J, Philip ML, Raju BN. Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital. J Rep Pharm Sci. 2021;10(1):e147100. doi: https://doi.org/10.4103/jrptps.JRPTPS_68_20

30
Apr
2019

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients

Ebrahim Salehifar,
Razieh Avan,
Ghasem Janbabaei,
Seyed Khalil Mousavi,
Fatemeh Faramarzi

Salehifar E, Avan R, Janbabaei G, Mousavi SK, Faramarzi F. Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients. Iran J Pharm Res. 2019;18(2):e126242. doi: https://doi.org/10.22037/ijpr.2019.1100663

30
Apr
2015

A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP

Kazem Anvari,
Mehdi Seilanian-Toussi,
Hossein Hosseinzad-Ashkiki,
Soodabeh Shahidsales

Anvari K, Seilanian-Toussi M, Hosseinzad-Ashkiki H, Shahidsales S. A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP. Int J Cancer Manag. 2015;8(2):e80594. doi:

30
Apr
2014

Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study

Kian Khodadad,
Adnan Khosravi,
Zahra Esfahani-Monfared,
Shirin Karimi,
Sharare Seifi

Khodadad K, Khosravi A, Esfahani-Monfared Z, Karimi S, Seifi S. Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study. Iran J Pharm Res. 2014;13(2):e125542. doi: https://doi.org/10.22037/ijpr.2014.1492

30
Sep
2013

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer

Leila Pourali,
Ali Taghizadeh kermani,
Mohammad Reza Ghavamnasiri,
Fahimeh Khoshroo,
Sare Hosseini,
Mehdi Asadi
,et al.

Pourali L, Taghizadeh kermani A, Ghavamnasiri MR, Khoshroo F, Hosseini S, et al. Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer. Int J Cancer Manag. 2013;6(3):e80423. doi:

Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles